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Kurepina3, E.M. Streicher1, R.M. Warren1, P.D.
van Helden1, L. Wangh2
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2 Brandeis University, Waltham, MA, USA
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Background: In 2006, the World Health Organization (WHO)
and the Stop TB partnership called for strengthening of diagnos-
tic services and highlighted the need for the development of rapid
diagnostics to ﬁght the tuberculosis pandemic. In 2011, WHO esti-
mated that approximately 630,000 (5.3%) of the 12 million TB
cases had multiple drug resistant (MDR)-TB, while more than 80
countries have reported cases of extremely drug-resistant (XDR)-
TB. Only a small fraction of reported cases (<20%) were correctly
diagnosed and even fewer were treated according to WHO stan-
dards. In response the WHO endorsed the Genotype® MTBDRplus
(version 1.0) line probe assay (LPA) in 2008 and theXpert®MTB/RIF
assay in 2010. But these tests only provide evidence for resistance
to isoniazid and/or rifampicin. There continues to be a critical need
for a more comprehensive convenient diagnostic technology. The
highly multiplexed LATE-PCR assay for M(X)DR-TB described here
was designed to meet that need.\
Our goal was to ﬁrmly establish that a highly multiplexed
Linear-After-the-Exponential (LATE) PCR single closed-tube assay
can simultaneously detect and distinguish multiple mutations in
multiple gene targets that are known to confer resistance to isoni-
azid, rifampicin, ethambutol, oﬂoxacin, amikacin, kanamycin and
capreomycin.
Methods & Materials: In this initial study, DNA from clini-
cal isolates with different rpoB, katG, embB, inhA promoter, gyrB,
gyrA and rrs genotypes were selected from a DNA bank housed at
Stellenbosch University. Each DNA samples was ampliﬁed and the
singled-strandedDNAproductswere scanned formutations at end-
point using the same mixture of Lights-On/Lights-Off Probes. The
resulting ﬂuorescent signatures were compared to that of H37Rv,
a pan-susceptible “wildtype” strain.
Results: Each clinical isolate harbouring a unique mutation had
its own, highly reproducible ﬂuorescent signature distinct from
that of H37Rv, as well as all other isolates with differentmutations.
Conclusion: This study achieved the intended transfer of the
Brandeis University technology to Stellenbosch University. This
study also demonstrates that this single tube multiplexed assay
can simultaneously distinguish the different mutations that confer
resistance to rifampicin, isoniazid, ethambutol, ﬂuoroquinolones,
aminoglycosides and ethionamide in less than three hours.
(Supported by NIH Grant R01 A1099532)
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Classiﬁcation of tuberculous meningitis using
Marais Criteria
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H. Coradin2, V. Gonzalez Pantaleon1
1 Universidad Iberoamericana Unibe, Santo
Domingo, Dominican Republic
2 Hospital Infantil Dr. Robert Read Cabral, Santo
Domingo, Dominican Republic
Background: Tuberculous meningitis (TBM) diagnosis is dif-
ﬁcult, being the worst prognostic form of extrapulmonary
tuberculosis. Diagnostic delays contribute signiﬁcantly tomortality
and neurologic sequelae.
Methods&Materials:Weperformed anobservational, descrip-
tive and transversal study applying new consensus criteria for the
deﬁnition of Meningeal Tuberculosis diagnosis and British Medical
Research Council stage prognosis. In the study period, 68 patients
were identiﬁed for tuberculous meningitis, 40 were excluded, and
the ﬁnal sample consisted of 28 cases
Results: The diagnostic group “Possible” was the most common
with 35.7%, followed by Deﬁnite with 28.6%, Probable 21.4%, and
14.3% were excluded as Non-tuberculous meningitis in which an
alternative diagnosis was established or considered dual disease.
60.71% were less than 5 years of age. 78.6% were male. 80.77%
patients had symptoms for more than 5 days. 88.46% patients
had focal neurological deﬁcits. 64% patients showed alteration of
consciousness. 64.3%underwentneuroimaging,which50%demon-
strated hydrocephalus. 75% of patients were in Stage III of the
prognostic British Medical Research Council classiﬁcation. 7.1%
died.
Conclusion: Classiﬁcation of tuberculous meningitis allows
early diagnosis and treatment. Tuberculous meningitis manifesta-
tions vary and TBM is usually diagnosed when brain damage has
already occurred.
http://dx.doi.org/10.1016/j.ijid.2014.03.1202
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Detection of toxigenic Clostridium difﬁcile by
Loop-Mediated Isothermal Ampliﬁcation
(LAMP)
P. Jayaratne
St. Joseph’s Healthcare, Hamilton, ON, Canada
Background: Clostridium difﬁcile-associated disease (CDAD) is a
leading cause of nosocomial diarrhea in adults. Therefore, rapid and
